ACTN4 p.Ile150Met Causes FSGS With Validation in Primary Fibroblasts and Immortalized Podocytes.
Kidney Int Rep
2026
11
2
Sodium glucose cotransporter 2 inhibition does not improve active lupus nephritis in MRLlpr/lpr mice.
Kidney Int
2026
109
1
211-216
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.
Am J Kidney Dis
2026
87
4
553-563.e1
Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023.
Kidney Int
2026
109
1
57-63
Alport Syndrome is a Partial Tubulointerstitial Disease of the Kidney.
Kidney Int Rep
2026
11
2
Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.
Am J Kidney Dis
2026
87
4
564-568
Impact of acute kidney injury in ≥65-year-old kidney donors on short- and long-term allograft outcomes.
Front Med (Lausanne)
2026
12
Gut microbiome alterations precede graft rejection in kidney transplantation patients.
Am J Transplant
2025
25
8
1643-1656
"Real world" medical care of patients with Fabry disease by primary care physicians, internists or general practitioners.
Cardiovasc Diagn Ther
2025
15
2
350-361
[Clinical, multimodal sonography of the kidneys and urinary tract - Update 2025].
Aktuelle Urol
2025
56
3
230-236